| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Donmienne Leung | Q92633360 |
| Jacqueline M Wurst | Q92633363 | ||
| Amita Datta-Mannan | Q92633367 | ||
| P2093 | author name string | Tao Liu | |
| Yiqing Feng | |||
| Ruben M Martinez | |||
| P2860 | cites work | Synthesis of site-specific antibody-drug conjugates using unnatural amino acids | Q24624489 |
| Assessing the Immunogenicity of Biopharmaceuticals | Q26751485 | ||
| Continuous cultures of fused cells secreting antibody of predefined specificity | Q26776979 | ||
| Antibody-drug conjugates as novel anti-cancer chemotherapeutics | Q26800175 | ||
| Microtubule-binding agents: a dynamic field of cancer therapeutics | Q27690249 | ||
| Antibody-drug conjugates for non-oncological indications. | Q46036446 | ||
| Targeted Delivery of an Anti-inflammatory PDE4 Inhibitor to Immune Cells via an Antibody-drug Conjugate | Q46120241 | ||
| Characterization and Higher-Order Structure Assessment of an Interchain Cysteine-Based ADC: Impact of Drug Loading and Distribution on the Mechanism of Aggregation | Q46602455 | ||
| Auristatin antibody drug conjugate physical instability and the role of drug payload | Q46639318 | ||
| Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs | Q46674963 | ||
| Photoinduced aggregation of a model antibody-drug conjugate | Q46742557 | ||
| CAT-02-106, a Site-Specifically Conjugated Anti-CD22 Antibody Bearing an MDR1-Resistant Maytansine Payload Yields Excellent Efficacy and Safety in Preclinical Models | Q47398646 | ||
| A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors | Q47732625 | ||
| Monoclonal Antibodies: A Review. | Q47804632 | ||
| Development and evaluation of β-galactosidase-sensitive antibody-drug conjugates. | Q47939022 | ||
| Discovery of Peptidomimetic Antibody-Drug Conjugate Linkers with Enhanced Protease Specificity. | Q48141386 | ||
| Efficient Preparation of Site-Specific Antibody-Drug Conjugates Using Cysteine Insertion | Q48184768 | ||
| Engineered cysteine antibodies: an improved antibody-drug conjugate platform with a novel mechanism of drug-linker stability. | Q49691160 | ||
| In vitro and in vivo activity of IMGN853, an Antibody-Drug Conjugate targeting Folate Receptor Alpha linked to DM4, in biologically aggressive endometrial cancers. | Q50027073 | ||
| High-Throughput Cysteine Scanning To Identify Stable Antibody Conjugation Sites for Maleimide- and Disulfide-Based Linkers. | Q50100291 | ||
| Chemical de-conjugation for investigating the stability of small molecule drugs in antibody-drug conjugates. | Q50931606 | ||
| Modulating Antibody-Drug Conjugate Payload Metabolism by Conjugation Site and Linker Modification. | Q51747586 | ||
| Challenges and new frontiers in analytical characterization of antibody-drug conjugates. | Q52401505 | ||
| Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications. | Q52593621 | ||
| Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs). | Q52704026 | ||
| Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. | Q53259778 | ||
| DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. | Q54204362 | ||
| An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer. | Q54439772 | ||
| Site-Specific Antibody Conjugation for ADC and Beyond. | Q55022669 | ||
| Antibody-Antisense Oligonucleotide Conjugate Downregulates a Key Gene in Glioblastoma Stem Cells. | Q55333253 | ||
| Glutamic acid-valine-citrulline linkers ensure stability and efficacy of antibody-drug conjugates in mice. | Q55385806 | ||
| Sortase A: A Model for Transpeptidation and Its Biological Applications | Q56888969 | ||
| Antibody drug conjugates: Progress, pitfalls, and promises | Q57159598 | ||
| Targeted delivery of antisense oligonucleotides to pancreatic β-cells | Q57813916 | ||
| A Traceless Vascular-Targeting Antibody-Drug Conjugate for Cancer Therapy | Q57911965 | ||
| Fucose-specific conjugation of hydrazide derivatives to a vascular-targeting monoclonal antibody in IgG format | Q57911974 | ||
| Oxidation Induced Destabilization of Model Antibody-Drug Conjugates | Q58593561 | ||
| Monodisperse polysarcosine-based highly-loaded antibody-drug conjugates | Q64056034 | ||
| Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study | Q64068732 | ||
| Acquired Resistance to Antibody-Drug Conjugates | Q64069325 | ||
| How the discovery of rituximab impacted the treatment of B-cell non-Hodgkin's lymphomas | Q64095781 | ||
| Dextramabs: A Novel Format of Antibody-Drug Conjugates Featuring a Multivalent Polysaccharide Scaffold | Q64106385 | ||
| GalNAc Conjugation Attenuates the Cytotoxicity of Antisense Oligonucleotide Drugs in Renal Tubular Cells. | Q64907210 | ||
| A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma. | Q64943573 | ||
| The human immune response to KS1/4-desacetylvinblastine (LY256787) and KS1/4-desacetylvinblastine hydrazide (LY203728) in single and multiple dose clinical studies | Q70138619 | ||
| Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate | Q80901453 | ||
| Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing | Q86081270 | ||
| Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers | Q86176716 | ||
| Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates | Q86200611 | ||
| Novel antibody-antibiotic conjugate eliminates intracellular S. aureus | Q27702570 | ||
| Reshaping human antibodies for therapy | Q28290936 | ||
| Introducing genetically encoded aldehydes into proteins | Q28298867 | ||
| Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency | Q28546010 | ||
| Current Status: Site-Specific Antibody Drug Conjugates | Q28829290 | ||
| Selective intracellular delivery of dexamethasone into activated endothelial cells using an E-selectin-directed immunoconjugate. | Q30792812 | ||
| Quantitative cumulative biodistribution of antibodies in mice: effect of modulating binding affinity to the neonatal Fc receptor | Q33573587 | ||
| Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. | Q33621610 | ||
| Molecularly defined antibody conjugation through a selenocysteine interface | Q33675575 | ||
| Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs | Q33746856 | ||
| Preparation of well-defined antibody-drug conjugates through glycan remodeling and strain-promoted azide-alkyne cycloadditions | Q34026374 | ||
| The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions | Q34110768 | ||
| Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N-Glycan of Native mAbs Provides Homogeneous and Highly Efficacious Antibody-Drug Conjugates | Q34480136 | ||
| The value of glucocorticoid co-therapy in different rheumatic diseases--positive and adverse effects | Q34597321 | ||
| Protein conjugation with genetically encoded unnatural amino acids | Q34838057 | ||
| Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate | Q34880994 | ||
| T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo | Q34998509 | ||
| Mechanisms involved in the side effects of glucocorticoids | Q35003894 | ||
| T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2. | Q35027806 | ||
| Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development | Q35105725 | ||
| Tunable degradation of maleimide-thiol adducts in reducing environments | Q35562329 | ||
| Building better monoclonal antibody-based therapeutics. | Q35817552 | ||
| Targeting the hemoglobin scavenger receptor CD163 in macrophages highly increases the anti-inflammatory potency of dexamethasone. | Q36142511 | ||
| Human anti-α3(IV)NC1 antibody drug conjugates target glomeruli to resolve nephritis. | Q36174495 | ||
| Targeted Delivery of LXR Agonist Using a Site-Specific Antibody-Drug Conjugate | Q36296686 | ||
| Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). | Q36356001 | ||
| Site-specific chemical protein conjugation using genetically encoded aldehyde tags | Q36399831 | ||
| A Pictet-Spengler ligation for protein chemical modification | Q36512416 | ||
| Facile and stabile linkages through tyrosine: bioconjugation strategies with the tyrosine-click reaction | Q36857353 | ||
| Heterogeneity of monoclonal antibodies | Q36935493 | ||
| Prodrug strategies in anticancer chemotherapy | Q36982570 | ||
| Anti-CD163-dexamethasone conjugate inhibits the acute phase response to lipopolysaccharide in rats | Q37014721 | ||
| Bridging disulfides for stable and defined antibody drug conjugates | Q38999187 | ||
| Site-specific antibody-drug conjugation through glycoengineering. | Q39023284 | ||
| Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates. | Q39028535 | ||
| Production of site-specific antibody-drug conjugates using optimized non-natural amino acids in a cell-free expression system | Q39033492 | ||
| Antibody-Antibiotic Conjugates: A Novel Therapeutic Platform against Bacterial Infections | Q39105280 | ||
| Strategies and challenges for the next generation of antibody-drug conjugates | Q39182945 | ||
| Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. | Q39408093 | ||
| Humanized Lewis-Y specific antibody based delivery of STAT3 siRNA. | Q39505101 | ||
| Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles | Q39638021 | ||
| Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer | Q39661572 | ||
| Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer | Q39664583 | ||
| Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. | Q39959127 | ||
| Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma | Q40333268 | ||
| Immunotoxins in the therapy of cancer: from bench to clinic | Q40576705 | ||
| A New Approach for the Treatment of Arthritis in Mice with a Novel Conjugate of an Anti-C5aR1 Antibody and C5 Small Interfering RNA. | Q40734548 | ||
| Immunoregulation by IL-7R-targeting antibody-drug conjugates: overcoming steroid-resistance in cancer and autoimmune disease. | Q41636928 | ||
| Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human | Q41874340 | ||
| Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry | Q42122777 | ||
| An immunosuppressive antibody-drug conjugate | Q42207099 | ||
| Site-specific and stoichiometric modification of antibodies by bacterial transglutaminase | Q42791810 | ||
| Next generation maleimides enable the controlled assembly of antibody-drug conjugates via native disulfide bond bridging | Q42871498 | ||
| Physicochemical stability of the antibody-drug conjugate Trastuzumab-DM1: changes due to modification and conjugation processes | Q42941707 | ||
| Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers | Q43262208 | ||
| Investigation into temperature-induced aggregation of an antibody drug conjugate | Q44437884 | ||
| Recent Developments in ADC Technology: Preclinical Studies Signal Future Clinical Trends | Q45728543 | ||
| CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies | Q37184796 | ||
| The delivery of therapeutic oligonucleotides | Q37210936 | ||
| Novel Targeted Therapy for Precursor B Cell Acute Lymphoblastic Leukemia: anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate. | Q37370563 | ||
| Potent antibody drug conjugates for cancer therapy | Q37469585 | ||
| Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin. | Q37527541 | ||
| From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-Drug Conjugates (ADCs). | Q37561359 | ||
| A general approach to site-specific antibody drug conjugates | Q37571113 | ||
| Site-specific antibody drug conjugates for cancer therapy | Q37593705 | ||
| Methods for site-specific drug conjugation to antibodies | Q37593707 | ||
| Site-specific antibody-polymer conjugates for siRNA delivery | Q37638814 | ||
| Protective role of anti-idiotypic antibodies in autoimmunity--lessons for type 1 diabetes | Q37656095 | ||
| Analytical methods for physicochemical characterization of antibody drug conjugates | Q37858385 | ||
| Sortagging: a robust and efficient chemoenzymatic ligation strategy. | Q38222365 | ||
| Unnatural amino acids in novel antibody conjugates | Q38243891 | ||
| Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides | Q38301148 | ||
| Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan | Q38374224 | ||
| Current possibilities of liquid chromatography for the characterization of antibody-drug conjugates | Q38661012 | ||
| Current Approaches for Absorption, Distribution, Metabolism, and Excretion Characterization of Antibody-Drug Conjugates: An Industry White Paper | Q38669790 | ||
| Pharmacokinetics and biodistribution of recently-developed siRNA nanomedicines | Q38674444 | ||
| SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression | Q38704805 | ||
| Antibacterial drug discovery in the resistance era. | Q38704810 | ||
| Physical and Chemical Stability of Antibody Drug Conjugates: Current Status | Q38730597 | ||
| Antibody Engineering for Pursuing a Healthier Future | Q38731632 | ||
| Novel Phosphate Modified Cathepsin B Linkers: Improving Aqueous Solubility and Enhancing Payload Scope of ADCs | Q38755088 | ||
| SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression | Q38766901 | ||
| Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates | Q38798481 | ||
| Discovery of Pyrophosphate Diesters as Tunable, Soluble, and Bioorthogonal Linkers for Site-Specific Antibody-Drug Conjugates | Q38805569 | ||
| A Polymer-Based Antibody-Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy | Q38859882 | ||
| Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index | Q38863927 | ||
| Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers | Q38881961 | ||
| In Vitro and In Vivo Evaluation of Cysteine Rebridged Trastuzumab-MMAE Antibody Drug Conjugates with Defined Drug-to-Antibody Ratios. | Q38884490 | ||
| Effect of attachment site on stability of cleavable antibody drug conjugates. | Q38914011 | ||
| Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB-siRNA conjugates. | Q38924311 | ||
| Antibody-drug conjugates: recent advances in conjugation and linker chemistries. | Q38981429 | ||
| Assessment of physical stability of an antibody drug conjugate by higher order structure analysis: impact of thiol- maleimide chemistry | Q87166084 | ||
| Biophysical Properties and Heating-Induced Aggregation of Lysine-Conjugated Antibody-Drug Conjugates | Q88296422 | ||
| Immunogenicity of biologic therapies: causes and consequences | Q88439230 | ||
| The "less-is-more" in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity | Q88590150 | ||
| Impact of Payload Hydrophobicity on the Stability of Antibody-Drug Conjugates | Q88889162 | ||
| Tumor stroma-targeted antibody-drug conjugate triggers localized anticancer drug release | Q88972041 | ||
| Development of Anti-CD74 Antibody-Drug Conjugates to Target Glucocorticoids to Immune Cells | Q89164062 | ||
| The Increasingly Human and Profitable Monoclonal Antibody Market | Q89265567 | ||
| Developing an Antibody-Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein | Q90207975 | ||
| Current Advancements in Addressing Key Challenges of Therapeutic Antibody Design, Manufacture, and Formulation | Q90212011 | ||
| Enzyme-Based Labeling Strategies for Antibody-Drug Conjugates and Antibody Mimetics | Q90212151 | ||
| Antibodies to watch in 2019 | Q90270674 | ||
| Hydrophobicity drives the systemic distribution of lipid-conjugated siRNAs via lipid transport pathways | Q90392447 | ||
| Exploration of Pyrrolobenzodiazepine (PBD)-Dimers Containing Disulfide-Based Prodrugs as Payloads for Antibody-Drug Conjugates | Q90440372 | ||
| Natural Product Bis-Intercalator Depsipeptides as a New Class of Payloads for Antibody-Drug Conjugates | Q90447703 | ||
| A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML | Q90473342 | ||
| Homogeneous antibody-drug conjugates via site-selective disulfide bridging | Q90550029 | ||
| Treating Disease at the RNA Level with Oligonucleotides | Q90849565 | ||
| Bioconjugated Oligonucleotides: Recent Developments and Therapeutic Applications | Q90876346 | ||
| Nicotinamide Phosphoribosyltransferase Inhibitor as a Novel Payload for Antibody-Drug Conjugates | Q91051867 | ||
| Novel PIKK inhibitor antibody-drug conjugates: Synthesis and anti-tumor activity | Q91097992 | ||
| Antibody-Drug Conjugates with Pyrrole-Based KSP Inhibitors as the Payload Class | Q91284515 | ||
| Cutting-edge multi-level analytical and structural characterization of antibody-drug conjugates: present and future | Q91301745 | ||
| Conjugation of Emtansine Onto Trastuzumab Promotes Aggregation of the Antibody-Drug Conjugate by Reducing Repulsive Electrostatic Interactions and Increasing Hydrophobic Interactions | Q91421589 | ||
| The Properties of Cysteine-Conjugated Antibody-Drug Conjugates Are Impacted by the IgG Subclass | Q91747254 | ||
| Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer | Q91750575 | ||
| Cleavable linkers in antibody-drug conjugates | Q91789686 | ||
| Quantification of siRNA-Antibody Conjugates in Biological Matrices by Triplex-Forming Oligonucleotide ELISA | Q91880454 | ||
| An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugates | Q92040902 | ||
| Site-Specific Bioconjugation Using SMARTag® Technology: A Practical and Effective Chemoenzymatic Approach to Generate Antibody-Drug Conjugates | Q92097984 | ||
| Antibody-Oligonucleotide Conjugates as Therapeutic, Imaging, and Detection Agents | Q92145982 | ||
| The Neonatal Fc Receptor (FcRn): A Misnomer? | Q92239387 | ||
| Insights from capillary electrophoresis approaches for characterization of monoclonal antibodies and antibody drug conjugates in the period 2016-2018 | Q92289562 | ||
| Antibody-drug therapeutic conjugates: Potential of antibody-siRNAs in cancer therapy | Q92599587 | ||
| Site-specific antibody-drug conjugate heterogeneity characterization and heterogeneity root cause analysis | Q92739502 | ||
| Antibody-drug conjugates- stability and formulation | Q92799724 | ||
| Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates | Q93020719 | ||
| Antibody-drug conjugates for cancer | Q93068497 | ||
| Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes | Q93384466 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2 | |
| P577 | publication date | 2020-01-08 | |
| P1433 | published in | Antibodies (Basel) | Q27724345 |
| P1476 | title | Antibody Conjugates-Recent Advances and Future Innovations | |
| P478 | volume | 9 |
Search more.